Clinical Trials – Talk Bio

Capricor Therapeutics Reports Positive Phase 3 HOPE-3 Trial Results for Deramiocel in Duchenne Muscular Dystrophy, Planning FDA Resubmission

3 hours ago talkbio0Tagged Capricor Therapeutics, cardiac function preservation, Clinical Trials, deramiocel, HOPE-3 trial, Muscular Dystrophy, Duchenne, Phase 3 clinical trial, regulatory approval pathway, Rejection, United States Food and Drug Administration, upper limb function

Capricor Therapeutics; Deramiocel; Duchenne muscular dystrophy; HOPE-3 trial; Phase 3 clinical trial; FDA rejection; cardiac function preservation; upper limb function; clinical trial results; regulatory approval pathway

Imvax Shares Positive Phase 2b Data for IGV-001 Glioblastoma Treatment and Plans FDA Meeting

10 hours ago talkbio0Tagged Clinical Trials, Glioblastoma, IGF-1R Antisense Oligodeoxynucleotide-treated Autologous Glioma Cells IGV-001, Immunotherapy, Imvax, meeting, Overall Survival, United States Food and Drug Administration

Imvax; IGV-001; glioblastoma; Phase 2b trial; overall survival; FDA meeting; immunotherapy; clinical trial; glioblastoma treatment

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at CTAD Conference

2 days ago talkbio0Tagged access program, Alzheimer 's disease, Clinical Trials, Cognition Therapeutics, CTAD, Lewy bodies, Neurodegenerative Disorders, Phase 3 clinical trial, Presenile dementia, sigma-2 receptor, Zervimesine

Cognition Therapeutics; Zervimesine; CT1812; Phase 3 clinical trial; Alzheimer’s disease; Clinical Trials on Alzheimer’s Disease (CTAD); neurodegenerative diseases; sigma-2 receptor; dementia with Lewy bodies; expanded access program

Whitehawk Therapeutics Appoints Margaret Dugan as Chief Medical Officer

2 days ago talkbio0Tagged Chief Medical Officer, Chronic multifocal osteomyelitis, Clinical Trials, Dracen Pharmaceuticals, Drug Development, Margaret Dugan, Neoplasms, Novartis, Schrödinger, therapeutic autologous dendritic cells, Whitehawk Therapeutics

Whitehawk Therapeutics; Margaret Dugan; Chief Medical Officer; CMO; oncology; ADC; drug development; clinical trials; Novartis; Dracen Pharmaceuticals; Schrödinger

Tessera Therapeutics Advances Gene Writing Technology with Major Funding and Strategic Partnerships

2 days ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, ARPA-H grant, CAR-T, Clinical Trials, Gene Writing, genome engineering, in vivo, Lipid Nanoparticles, Partnership, Regeneron, Tessera, TSRA-196

Tessera Therapeutics; Gene Writing; in vivo CAR-T; ARPA-H grant; Regeneron partnership; TSRA-196; alpha-1 antitrypsin deficiency; Lipid Nanoparticles; in vivo genome engineering; clinical trials

Generate:Biomedicines Launches Global Phase 3 Trials for AI-Engineered Anti-TSLP Antibody GB-0895 in Severe Asthma

2 days ago talkbio0Tagged AI-engineered antibody, Asthma, Biomedicines, Clinical Trials, GB-0895, Generate, Phase 3, Programmable Biology, Severe (severity modifier), SOLAIRIA-1, SOLAIRIA-2, thymic stromal lymphopoietin, TSLP gene

Generate:Biomedicines; GB-0895; Phase 3 clinical trials; TSLP; thymic stromal lymphopoietin; severe asthma; AI-engineered antibody; programmable biology; SOLAIRIA-1; SOLAIRIA-2

Keytruda Breaks New Ground with FDA Approval for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

3 days ago talkbio0Tagged Adjuvant Therapy, Approved, Clinical Trials, Event-Free Survival, Gene Expression, KEYNOTE-689 trial, Keytruda, Neoadjuvant Therapy, PD-L1, pembrolizumab, perioperative, Squamous cell carcinoma of the head and neck, United States Food and Drug Administration

Keytruda; pembrolizumab; perioperative treatment; head and neck squamous cell carcinoma; HNSCC; FDA approval; KEYNOTE-689 trial; neoadjuvant therapy; adjuvant therapy; PD-L1 expression; event-free survival; clinical trial

BostonGene to Showcase Transformative Impact of AI-Driven Profiling with Six Abstracts at the 67th American Society of Hematology Annual Meeting & Exposition

1 week ago talkbio0Tagged 67th, AI-driven, annual, Asymmetric Septal Hypertrophy, Biological Markers, BostonGene, Clinical Trials, Hematology (discipline), immune profiling, meeting, Molecular Profiling, Multiple Myeloma, Neoplasms, Precision - temporal, Stratification

BostonGene; AI-driven molecular profiling; hematology; 67th ASH Annual Meeting; immune profiling; multiple myeloma; patient stratification; clinical trials; biomarkers; precision oncology

Johnson & Johnson Halts Phase 2 Alzheimer’s Trial After Tau Antibody Failure

1 week ago talkbio0Tagged Alzheimer 's disease, Clinical Failure, Clinical Trials, discontinued, Johnson & Johnson, posdinemab, tau-targeting antibody

Johnson & Johnson; Alzheimer’s disease; tau-targeting antibody; posdinemab; Phase 2b AuTonomy trial; clinical failure; trial discontinued

As Drug Resistance Rises, GramEye and GSK Advance New AI-Led Infectious Disease Research

1 week ago talkbio0Tagged AI-driven, Antibiotics, Antimicrobial Resistance, Clinical Trials, Communicable Diseases, Drug Discovery, Gram-negative bacteria, GramEye, Mycoses, research, SmithKline Beecham, Staphylococcus aureus, superbugs

antimicrobial resistance (AMR); GramEye; GSK; AI-driven drug discovery; Gram-negative bacteria; Staphylococcus aureus; fungal infections; novel antibiotics; superbugs; infectious disease research; clinical trials